A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States..
Purpose of Review: This is a comprehensive review of the literature regarding the use of Lofexidine for opiate withdrawal symptoms. It covers the background and necessity of withdrawal programs and the management of withdrawal symptoms and then covers the existing evidence of the use of Lofexidine for this purpose.
Recent Findings: Opiate abuse leads to significant pain and suffering. However, withdrawal is difficult and often accompanied by withdrawal symptoms and renewed cravings. These symptoms are driven mostly by signaling in the locus coeruleus and the mesolimbic system and a rebound increase in noradrenaline, producing symptoms such as anxiety, gastrointestinal upset, and tension. Lofexidine, an alpha-2 agonist, can be used to manage acute withdrawal symptoms before starting maintenance treatment with either methadone or buprenorphine. Lofexidine, if FDA approved for management of withdrawal symptoms and has been proved to be both effective and safe.
Summary: Opiate addiction is increasing and plaguing the western world and specifically the U.S. It takes a large toll on both a personal and societal level and carries a high cost. Withdrawal is difficult, both related to withdrawal symptoms and renewed cravings. Lofexidine has been shown to be effective in reducing the former and could potentially aid in recovery and withdrawal.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Psychopharmacology bulletin - 50(2020), 3 vom: 23. Juli, Seite 76-96 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Urits, Ivan [VerfasserIn] |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 10.12.2021 Date Revised 14.12.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM313086338 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313086338 | ||
| 003 | DE-627 | ||
| 005 | 20231225145819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313086338 | ||
| 035 | |a (NLM)32733113 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States. | ||
| 520 | |a Purpose of Review: This is a comprehensive review of the literature regarding the use of Lofexidine for opiate withdrawal symptoms. It covers the background and necessity of withdrawal programs and the management of withdrawal symptoms and then covers the existing evidence of the use of Lofexidine for this purpose | ||
| 520 | |a Recent Findings: Opiate abuse leads to significant pain and suffering. However, withdrawal is difficult and often accompanied by withdrawal symptoms and renewed cravings. These symptoms are driven mostly by signaling in the locus coeruleus and the mesolimbic system and a rebound increase in noradrenaline, producing symptoms such as anxiety, gastrointestinal upset, and tension. Lofexidine, an alpha-2 agonist, can be used to manage acute withdrawal symptoms before starting maintenance treatment with either methadone or buprenorphine. Lofexidine, if FDA approved for management of withdrawal symptoms and has been proved to be both effective and safe | ||
| 520 | |a Summary: Opiate addiction is increasing and plaguing the western world and specifically the U.S. It takes a large toll on both a personal and societal level and carries a high cost. Withdrawal is difficult, both related to withdrawal symptoms and renewed cravings. Lofexidine has been shown to be effective in reducing the former and could potentially aid in recovery and withdrawal | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic opiate use | |
| 650 | 4 | |a chronic pain | |
| 650 | 4 | |a clonidine | |
| 650 | 4 | |a methadone | |
| 650 | 4 | |a opioid use disorder | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Clonidine |2 NLM | |
| 650 | 7 | |a MN3L5RMN02 |2 NLM | |
| 650 | 7 | |a lofexidine |2 NLM | |
| 650 | 7 | |a UI82K0T627 |2 NLM | |
| 700 | 1 | |a Patel, Anjana |e verfasserin |4 aut | |
| 700 | 1 | |a Zusman, Robbie |e verfasserin |4 aut | |
| 700 | 1 | |a Virgen, Celina Guadalupe |e verfasserin |4 aut | |
| 700 | 1 | |a Mousa, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Amnon A |e verfasserin |4 aut | |
| 700 | 1 | |a Kassem, Hisham |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Jai Won |e verfasserin |4 aut | |
| 700 | 1 | |a Hasoon, Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychopharmacology bulletin |d 1966 |g 50(2020), 3 vom: 23. Juli, Seite 76-96 |w (DE-627)NLM000009520 |x 2472-2448 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2020 |g number:3 |g day:23 |g month:07 |g pages:76-96 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2020 |e 3 |b 23 |c 07 |h 76-96 | ||